Pfizer’s maternal RSV vaccine candidate accepted for FDA priority review
22nd February 2023
PM Live
Pfizer’s US application for its respiratory syncytial virus (RSV) maternal vaccine candidate to help protect against the complications of the disease in infants has been accepted for priority review by the US Food and Drug Administration (FDA).
The single-dose vaccine is administered in the late second to third trimester of pregnancy. The antibodies triggered by the vaccine are then passed to the foetus to protect infants against RSV from birth to the first six months of life, when they are most vulnerable.